UK Cost Agency Recommends Teriflunomide (Aubagio) for MS

December 06, 2013

By Reuters Staff

LONDON (Reuters) Dec 06 - Britain's healthcare cost watchdog NICE has recommended that the state health service use Sanofi's new multiple sclerosis pill teriflunomide (Aubagio), which will be supplied at a discount.

The National Institute for Health and Clinical Excellence (NICE) - the body that decides if drugs should be paid for - said on Friday its final draft guidance recommended Aubagio for adults with relapsing-remitting multiple sclerosis.

The drug's list price is 13,529 pounds ($22,100) per patient a year but the size of the discount has not been disclosed.

On Thursday, NICE said it needed more information before deciding if a separate Sanofi drug for the disease - the injectable treatment Lemtrada (alemtuzumab) - was worth using.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: